Skip to main content

Table 3 Subgroup analysis of association between BPs and BMD for each variable

From: Effects of bisphosphonates in preventing periprosthetic bone loss following total hip arthroplasty: a systematic review and meta-analysis

Variable No. of trials No. of participants MD 95% CI p value
BPs Control
1 year after THA
 Type of THA
  Cemented 2 38 31 0.06 0.00–0.13 0.76
  Uncemented 9 202 194 0.05 0.02–0.09
 Treatment duration of BPs
   ≤ 6 months 5 96 88 0.04 − 0.01–0.10 0.32
   > 6 months 6 124 122 0.07 0.04–0.09
2–4 year after THA
 Type of THA
  Cemented 1 20 18 0.05 0.02–0.09 0.46
  Uncemented 4 80 88 0.07 0.03–0.11
 Treatment duration of BPs
   ≤ 6 months 4 86 86 0.03 − 0.03–0.09 0.32
   > 6 months 2 36 42 0.06 0.03–0.10
≥ 5 year after THA
 Type of THA
  Cemented 0 0 0 Not estimable Not estimable NA
  Uncemented 3 54 45 0.09 0.07–0.11
 Treatment duration of BPs
   ≤ 6 months 3 54 48 0.03 − 0.03–0.10 0.12
   > 6 months 1 18 16 0.09 0.07–0.11
  1. THA total hip arthroplasty, BPs bisphosphonates, MD mean differences, CI confidence interval, NA not applicable